Sterilization Methods for PLGA Drug Products: Gamma, EtO, and Aseptic Processing Compared

Introduction:

Selecting the correct sterilization methods for PLGA drug products is one of the most consequential decisions in pharmaceutical formulation development. Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable, biocompatible polymer widely used in long-acting injectable (LAI) formulations, microspheres, nanoparticles, and implantable drug delivery systems. Its sensitivity to heat, moisture, and ionizing radiation makes standard terminal sterilization approaches inadequate or problematic, requiring a method-by-method evaluation based on the specific product, dose, and regulatory pathway.

Unlike conventional small-molecule injectables that can often be terminally sterilized by autoclaving or filtration alone, PLGA-based drug products present a unique set of challenges: the polymer itself is hydrolytically labile, drug encapsulation efficiency can be disrupted, and any process that alters the polymer’s molecular weight or crystallinity can fundamentally change the drug release profile — potentially invalidating the entire clinical program.

At ResolveMass Laboratories Inc., we support pharmaceutical companies and biotech innovators navigating the complex landscape of PLGA formulation development, characterization, and regulatory submission. In this article, our analytical experts compare the three primary sterilization strategies used for PLGA drug products — gamma irradiation, ethylene oxide (EtO), and aseptic processing — across dimensions of polymer compatibility, drug stability, regulatory acceptance, and practical implementation.

Summary:

Sterilization methods for PLGA drug products must preserve polymer integrity and drug release kinetics while achieving a sterility assurance level (SAL) of 10⁻⁶.
Gamma irradiation can cause free-radical-induced polymer degradation and molecular weight reduction — suitable at controlled doses for certain PLGA implants but requires extensive validation.
Ethylene oxide (EtO) sterilization avoids radiation damage but introduces residue risks and may affect surface properties of PLGA microspheres — accepted under strict ICH/FDA residue limits.
Aseptic processing is the preferred sterilization strategy for most PLGA injectable formulations, eliminating terminal sterilization risks but demanding rigorous cleanroom controls and process validation.
Terminal moist heat sterilization (autoclaving) is not compatible with PLGA due to hydrolytic degradation at the temperatures and moisture levels required.
Regulatory expectations from FDA, EMA, and ICH Q8/Q11 favor the least-damaging approach; aseptic fill/finish with a sterile-filtered drug substance is currently the industry gold standard.
ResolveMass Laboratories provides analytical characterization services to validate sterilization method selection, including molecular weight analysis (GPC/SEC), in vitro drug release testing, and physicochemical stability studies.

Have a technical question about PLGA sterilization methods or need analytical guidance?

📩 Reach out through our contact portal:

1: What Makes PLGA Sensitive to Sterilization?

PLGA is uniquely vulnerable to sterilization stress because of its fundamental chemistry. The ester backbone undergoes hydrolysis under aqueous and thermal conditions, and the polymer’s amorphous or semi-crystalline structure can be altered by ionizing radiation or reactive gases.

Key polymer properties that make sterilization method selection critical include:

Hydrolytic susceptibility: PLGA degrades in the presence of water via ester bond cleavage — making autoclave (steam) sterilization incompatible.
Radiation sensitivity: High-energy radiation generates free radicals within the polymer matrix, accelerating chain scission and molecular weight (MW) reduction.
Surface chemistry: EtO gas interacts with surface functional groups, raising concerns about residual alkylating agents in drug-loaded microspheres.
Encapsulated drug sensitivity: Many biopharmaceuticals, peptides, and small molecules loaded into PLGA can be independently sensitive to radiation, heat, or reactive chemicals.
Release profile dependence on MW and porosity: Any method that alters PLGA Mw, PDI, or microstructure may shift the in vitro/in vivo drug release rate — a critical Quality Attribute (CQA).

2: Gamma Irradiation for PLGA Drug Products

Gamma irradiation achieves sterilization by directing high-energy photons (from cobalt-60 decay) through the product. It achieves a sterility assurance level (SAL) of 10⁻⁶ at standard doses (typically 25–40 kGy) and is widely used in terminal sterilization of medical devices and some injectable drug products.

Advantages of Gamma Irradiation

Penetrating — suitable for products in final sealed packaging.
No residues — unlike EtO, gamma leaves no chemical residues.
Validated regulatory precedent — accepted by FDA and EMA for many sterile drug products.
Scalable — industrial gamma irradiation facilities offer high throughput.

Challenges for PLGA Products

Gamma irradiation causes free radical generation within the PLGA polymer matrix. These radicals initiate chain scission, leading to:

Molecular weight (Mw) reduction of PLGA — measurable by GPC/SEC analysis.
Shift in polydispersity index (PDI) — affecting drug release predictability.
Altered glass transition temperature (Tg) — measurable by DSC.
Oxidative degradation of encapsulated drugs — particularly peptides and proteins.
Accelerated in vitro drug release — potentially invalidating bioequivalence and clinical data.

Studies published in the Journal of Controlled Release and International Journal of Pharmaceutics have demonstrated that PLGA microspheres and implants irradiated at doses of 25 kGy or higher show statistically significant reductions in Mw and changes in drug release kinetics. Low-dose gamma (10–15 kGy) combined with antioxidant excipients has been explored as a mitigation strategy for select formulations but is not universally applicable.

When Is Gamma Irradiation Considered for PLGA?

PLGA implants where no biological drug is encapsulated (e.g., drug-free scaffolds, blank microspheres).
Products where dose-response studies confirm acceptable Mw change within validated specifications.
Combination products (device-drug) where device terminal sterilization requirements drive the method.

ResolveMass Laboratories offers GPC/SEC molecular weight analysis, DSC characterization, and in vitro drug release testing to support gamma irradiation validation and impact assessment for PLGA formulations.

3: Ethylene Oxide (EtO) Sterilization for PLGA Drug Products

Ethylene oxide sterilization works by alkylating nucleic acids and proteins in microorganisms, achieving SAL 10⁻⁶ at ambient or mildly elevated temperatures (typically 30–60°C). Because EtO operates at low temperatures, it avoids the thermal degradation associated with autoclaving — making it an option for temperature-sensitive polymer systems.

Advantages of EtO Sterilization

Low temperature process — compatible with thermolabile polymers and drug molecules.
No ionizing radiation — avoids free radical chain scission in PLGA.
Penetrating gas — can reach complex geometries in final packaging.
Wide regulatory acceptance — standard in medical device and pharmaceutical industries (FDA 21 CFR, ISO 11135).

Challenges for PLGA Drug Products

The principal concern with EtO sterilization of PLGA formulations is residual ethylene oxide and ethylene chlorohydrin (ECH), a reaction by-product. The FDA and ICH Q3C impose strict residue limits, and the porous, high surface-area architecture of PLGA microspheres and nanoparticles may complicate outgassing and residue removal:

Residue entrapment in polymer pores — potential for elevated residue levels relative to non-porous dosage forms.
Ethylene chlorohydrin formation — particularly when moisture or chloride ions are present.
Protein and peptide payload sensitivity — EtO can alkylate drug molecules if exposed.
Surface modification — EtO exposure may alter PLGA surface chemistry and hydrophilicity.
Lengthy aeration/outgassing — adds significant manufacturing time and cost.

Regulatory Considerations for EtO and PLGA

EtO residue testing is required per ISO 10993-7 and ICH Q3C. For parenterals, the tolerable contact limit (TCL) for EtO is ≤1 mg per device/product. Submission dossiers (NDA/ANDA/BLA) must include residue testing data demonstrating compliance. ResolveMass Laboratories offers headspace GC and GC-MS residue quantification for EtO and ECH in PLGA drug products to support regulatory submissions.

4: Aseptic Processing: The Preferred Sterilization Strategy for PLGA Injectables

Aseptic processing is the process of manufacturing sterile drug products in a controlled cleanroom environment without applying a terminal sterilization step to the final container. For most PLGA drug products — particularly injectable microspheres, LAI suspensions, and nanoparticle formulations — aseptic processing is the regulatory gold standard and the method of choice.

In aseptic fill/finish for PLGA drug products, the polymer, drug, and excipients are each sterilized separately (typically via membrane filtration for solutions or aseptic processing of sterile bulk), then combined and filled under ISO 5 (Grade A) conditions.

Key Steps in Aseptic Processing of PLGA Drug Products

Sterilization of drug substance: bioburden-reduced or sterile-filtered API solution.
PLGA polymer sterilization: gamma-irradiated bulk polymer (low dose, pre-validated) or aseptic recrystallization.
Solvent sterilization: 0.22 µm filtration of organic solvents used in microencapsulation.
Microencapsulation under ISO 5 conditions: solvent evaporation, spray drying, or nanoprecipitation in a classified environment.
Filling and sealing: aseptic vial fill/finish with validated closure integrity.
Environmental and process monitoring: viable/non-viable particle counts, media fills, personnel gowning qualification.

Advantages of Aseptic Processing for PLGA

No polymer degradation — PLGA molecular weight and microstructure remain intact.
No drug degradation via radiation or reactive chemicals.
Preserves encapsulation efficiency — drug content uniformity maintained.
Preserves in vitro release profile — critical for LAI and sustained-release claims.
Regulatory preference — FDA Guidance on Sterile Drug Products notes aseptic processing as the preferred approach when terminal sterilization is not feasible.

Challenges of Aseptic Processing

High facility investment — requires Grade A/B (ISO 5/7) classified cleanroom environment.
Complex process validation — media fill studies, environmental monitoring programs, and personnel qualification are required.
Container closure integrity testing (CCIT) — critical to confirm sterile barrier maintenance.
Bioburden control throughout manufacturing — starting materials and intermediates must meet strict limits.
No terminal sterility backup — the process itself IS the sterility assurance strategy.

ResolveMass Laboratories provides analytical support for aseptic process validation of PLGA drug products, including in vitro drug release testing, particle size analysis, encapsulation efficiency determination, and GPC/SEC molecular weight characterization.

5: Sterilization Methods for PLGA Drug Products: Side-by-Side Comparison

Parameter	Gamma Irradiation	EtO Sterilization	Aseptic Processing	Terminal Moist Heat
Mechanism	Ionizing radiation breaks DNA/RNA	Alkylation of cellular proteins	Controlled sterile manufacturing	Steam at 121°C / 15 psi
PLGA Compatibility	⚠ Moderate – may degrade	⚠ Moderate – residue risk	✅ Best – no polymer stress	❌ Not suitable – hydrolysis
Polymer Impact	Free radical generation; MW reduction	Surface exposure; residue concern	None (process-based)	Severe hydrolytic degradation
Drug Stability Risk	Oxidation, fragmentation	Chemical modification	Lowest risk	Complete drug release/loss
Sterility Assurance	SAL 10⁻⁶ achievable	SAL 10⁻⁶ achievable	SAL 10⁻⁶ (validated)	SAL 10⁻⁶ achievable
Regulatory Precedent	ICH Q8/Q11; FDA accepted	FDA/EMA accepted	FDA/EMA preferred for labile	Not applicable for PLGA
Scalability	High – industrial scale	High	Moderate – complex facility	High – but not relevant
Cost	Moderate	Moderate–High	High (cleanroom, fill/finish)	Low – but not viable
Common PLGA Use	PLGA implants (dose-dependent)	Microspheres (limited)	Preferred for most injectables	Not used

6: Regulatory Framework for Sterilization Method Selection

The regulatory agencies provide clear frameworks for sterilization method selection and validation:

FDA Guidance

FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing (2004) establishes expectations for aseptic fill/finish validation, environmental monitoring, and container closure integrity.
FDA’s Quality by Design (QbD) principles (ICH Q8, Q9, Q10, Q11) require sterilization method selection to be justified as part of the design space, linking the method to Critical Quality Attributes (CQAs) including sterility, drug release, and polymer integrity.
21 CFR Part 211 governs current Good Manufacturing Practices (cGMP) for finished pharmaceuticals, including sterilization process controls.

EMA and ICH Guidelines

ICH Q8(R2) — Pharmaceutical Development: requires systematic evaluation of sterilization approach in the development report.
EMA Guideline on the sterilization of the medicinal product, active substance, and primary container: advocates the hierarchy of sterilization options — terminal sterilization preferred, aseptic processing when terminal methods are not feasible.
ICH Q3C — Residual Solvents and Q3D — Elemental Impurities: relevant for EtO residue and catalyst residue testing in PLGA production.

Key Regulatory Principle: The Hierarchy of Sterilization

Regulatory agencies universally follow a sterilization hierarchy that prioritizes terminal sterilization (e.g., moist heat or gamma) where product stability allows, and permits aseptic processing only when terminal methods are incompatible with product quality. For PLGA drug products, the well-documented polymer and drug sensitivity to heat and radiation means aseptic processing is routinely justified and accepted — provided the validation package is robust and the facility meets cGMP requirements.

7: Analytical Characterization to Support Sterilization Method Validation

Regardless of which sterilization approach is selected, a robust analytical characterization program is essential to demonstrate that the chosen method does not adversely affect product quality. ResolveMass Laboratories Inc. provides the following analytical services specifically relevant to PLGA sterilization validation:

Molecular Weight and Polymer Integrity

GPC/SEC (Gel Permeation / Size Exclusion Chromatography): Quantifies Mw, Mn, and PDI of PLGA before and after sterilization — the definitive test for radiation-induced chain scission.
DSC (Differential Scanning Calorimetry): Measures glass transition temperature (Tg) and crystallinity changes indicative of polymer structural alteration.
FTIR / NMR Spectroscopy: Identifies chemical modifications in PLGA structure post-sterilization.

Drug Stability and Release

In vitro drug release (IVRT): Validated USP/ICH protocols to assess release profile pre- vs. post-sterilization — detects shifts in burst release, release rate, and total recovery.
Encapsulation efficiency (HPLC/UV): Confirms drug content uniformity is preserved post-sterilization.
Forced degradation studies: Radiation and oxidative stress studies that model gamma irradiation impact on the API.

Residue and Safety Testing

EtO / ECH residue quantification (headspace GC, GC-MS): For EtO-sterilized PLGA products, per ISO 10993-7 and ICH Q3C.
Bioburden and sterility testing (USP <71>, <1227>): Pre-sterilization bioburden enumeration to validate the sterilization challenge.
Container closure integrity testing (CCIT): Dye ingress, vacuum decay, or headspace analysis for aseptically filled PLGA product vials.

8: Practical Considerations: Matching the Method to Your PLGA Product

Not all PLGA formulations are equivalent — and the ideal sterilization approach depends on specific product characteristics:

PLGA Microspheres for LAI (Long-Acting Injectables)

Aseptic processing is the overwhelmingly preferred approach. Products like naltrexone, risperidone, aripiprazole, and leuprolide microsphere formulations are manufactured using aseptic microencapsulation followed by lyophilization and aseptic fill — consistent with FDA-approved LAI products currently on the market.

PLGA Implants and Rods

Gamma irradiation at controlled doses (10–25 kGy) has been used for select PLGA implants, particularly where the drug load is stable to radiation and the polymer Mw change is within the validated specification window. Dose-mapping and MW impact studies are mandatory.

PLGA Nanoparticles for Oncology

Aseptic processing or sterile filtration (where particle size permits sub-0.22 µm filtration) is preferred. Gamma irradiation at nanoparticle scale carries higher surface-to-volume ratio concerns, amplifying radiation sensitivity per unit mass.

PLGA-Based Combination Products

When PLGA is part of a device-drug combination product, device sterilization requirements (often gamma or EtO per ISO 11135/11137) may conflict with drug stability needs — requiring a risk-based justification or dual-strategy approach, which must be prospectively discussed with the regulatory agency.

Conclusion:

The selection of sterilization methods for PLGA drug products requires a thorough understanding of polymer chemistry, drug substance sensitivity, regulatory expectations, and manufacturing capabilities. There is no universal answer: aseptic processing offers the greatest product quality protection for most PLGA injectables and LAIs; gamma irradiation may be viable for select implants with robust validation; and EtO sterilization is a constrained option that requires stringent residue control and careful surface compatibility evaluation. Terminal moist heat sterilization is not a viable path for PLGA.

The most scientifically and regulatorily defensible approach is one grounded in a systematic, data-driven comparison supported by comprehensive analytical characterization — from GPC/SEC molecular weight profiling and DSC thermal analysis to in vitro drug release testing and residue quantification.

ResolveMass Laboratories Inc. has deep expertise in the analytical characterization of PLGA-based drug delivery systems, including microspheres, nanoparticles, implants, and LAI formulations. Our scientists work with pharmaceutical developers, generic drug companies, and biotech firms across Canada and globally to generate the data packages needed to justify sterilization method selection in IND, NDA, ANDA, and BLA submissions.

Frequently Asked Questions:

1. Why is sterilizing PLGA drug products challenging?

PLGA drug products are difficult to sterilize because the polymer is highly sensitive to heat, moisture, radiation, and chemicals. These conditions can lead to polymer degradation and reduced molecular weight. As a result, drug release profiles may change significantly. Many PLGA formulations contain sensitive APIs such as peptides or proteins, which further complicates sterilization. Standard sterilization methods used for simple drugs may not be suitable. Therefore, specialized approaches are required to maintain both sterility and product quality.

2. How does Gamma sterilization affect PLGA formulations?

Gamma sterilization uses high-energy radiation that can generate free radicals within PLGA polymers. This often leads to chain scission and reduction in molecular weight. As a result, the degradation rate of PLGA may increase after sterilization. Drug release profiles can also become faster or less predictable. While gamma sterilization ensures strong sterility assurance, it may compromise formulation stability. Therefore, its suitability must be evaluated carefully through analytical testing and stability studies.

3. Is Ethylene Oxide (EtO) sterilization suitable for PLGA drug products?

EtO sterilization can be used for certain PLGA drug products, especially heat-sensitive implants and device-based systems. It operates at low temperatures, which helps preserve polymer structure. However, EtO may leave behind toxic residues such as ethylene oxide and ethylene chlorohydrin. These residues must be thoroughly removed through aeration and tested against regulatory limits. Compatibility with drug substances must also be confirmed. Therefore, EtO is suitable only when properly validated and controlled.

4. What is the advantage of aseptic processing for PLGA formulations?

Aseptic processing avoids exposing PLGA formulations to harsh terminal sterilization conditions. This helps preserve polymer molecular weight, drug stability, and controlled-release behavior. It is particularly useful for sensitive biologics such as peptides and proteins. However, it requires highly controlled manufacturing environments, sterile raw materials, and strict process validation. Cleanroom operations and environmental monitoring are critical. Despite its complexity, it is often the preferred method for injectable PLGA systems.

5. Which sterilization method is best for PLGA drug delivery systems?

There is no single best method for all PLGA drug delivery systems. Gamma sterilization is suitable for some stable devices but may degrade sensitive polymers. EtO is useful for heat-sensitive implants but requires strict residual control. Aseptic processing is preferred for injectable microspheres and nanoparticle formulations. The selection depends on drug stability, polymer sensitivity, and regulatory requirements. A risk-based approach supported by analytical data is essential for decision-making.

6. Does sterilization change the drug release profile of PLGA products?

Yes, sterilization can significantly alter drug release behavior in PLGA systems. Gamma irradiation may accelerate release by reducing polymer molecular weight. EtO typically has a smaller effect but may still influence stability indirectly. Aseptic processing generally preserves original release kinetics. Any change in polymer structure can affect degradation rate and diffusion mechanisms. Therefore, dissolution and stability studies are essential after sterilization.

Need expert support for PLGA drug product sterilization, gamma irradiation studies, or aseptic processing validation?

ResolveMass Laboratories Inc. provides advanced analytical solutions for pharmaceutical development and regulatory compliance.

Reference

Herczeg CK, Song J. Sterilization of polymeric implants: challenges and opportunities. ACS applied bio materials. 2022 Nov 1;5(11):5077-88.https://pubs.acs.org/doi/abs/10.1021/acsabm.2c00793
Galante R, Pinto TJ, Colaço R, Serro AP. Sterilization of hydrogels for biomedical applications: A review. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2018 Aug;106(6):2472-92. https://onlinelibrary.wiley.com/doi/abs/10.1002/jbm.b.34048
Holy CE, Cheng C, Davies JE, Shoichet MS. Optimizing the sterilization of PLGA scaffolds for use in tissue engineering. Biomaterials. 2000 Jan 1;22(1):25-31.https://www.sciencedirect.com/science/article/pii/S0142961200001368
Yaman A. Methods of Sterilization for Controlled Release Injectable and Implantable Preparations. InLong Acting Injections and Implants 2011 Sep 13 (pp. 459-473). Boston, MA: Springer US.https://link.springer.com/chapter/10.1007/978-1-4614-0554-2_22
Hunter GW. Basics of sterilization methods. InSterile Product Development: Formulation, Process, Quality and Regulatory Considerations 2013 Sep 3 (pp. 475-500). New York, NY: Springer New York.https://link.springer.com/chapter/10.1007/978-1-4614-7978-9_18

About the Author

Priyal Darji

Priyal Darji, B.Pharm, is an experienced professional in analytical chemistry and pharmaceutical formulation development. She has extensive hands-on expertise in method development, impurity profiling, characterization studies, polymer chemistry for novel drug delivery formulations, contributing to research and development projects within the pharmaceutical sector. Her work focuses on bridging analytical precision with innovative formulation science.